Using advanced imaging and genetic data to improve treatment predictions for triple negative breast cancer
INTEGRATING OMICS AND QUANTITATIVE IMAGING DATA IN CO-CLINICAL TRIALS TO PREDICT TREATMENT RESPONSE IN TRIPLE NEGATIVE BREAST CANCER
This study is looking at triple negative breast cancer to find out which treatments might work best for patients by using special models and advanced imaging techniques to understand their unique genetic and molecular markers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Baylor College of Medicine NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10688170 on NIH RePORTER |
What this research studies
This research focuses on triple negative breast cancer (TNBC), a particularly aggressive form of cancer that currently lacks effective targeted therapies. By utilizing patient-derived xenograft models, the study aims to identify genetic and molecular markers that can predict how well patients will respond to various treatments. Additionally, it integrates advanced imaging techniques, such as MRI, to enhance the understanding of treatment responses. The goal is to create a framework that allows for better prediction of treatment outcomes in patients based on both genetic and imaging data.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who are seeking treatment options.
Not a fit: Patients with other types of breast cancer or those who are not diagnosed with cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized treatment plans for patients with triple negative breast cancer, improving their chances of a positive response to therapy.
How similar studies have performed: Other research has shown promise in using similar approaches to integrate genetic and imaging data for predicting treatment responses in various cancers.
Where this research is happening
Houston, United States
- Baylor College of Medicine — Houston, United States (Active)
Researchers
- Principal investigator: Lewis, Michael T. — Baylor College of Medicine
- Study coordinator: Lewis, Michael T.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.